awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q40309222-15B2072B-62C1-4816-B9BC-337502FF739B
Q40309222-15B2072B-62C1-4816-B9BC-337502FF739B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40309222-15B2072B-62C1-4816-B9BC-337502FF739B
An antidote approach to reduce risk and broaden utility of antibody-based therapeutics.
P2860
Q40309222-15B2072B-62C1-4816-B9BC-337502FF739B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40309222-15B2072B-62C1-4816-B9BC-337502FF739B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2003639b676f87fd92d762e445579e14764398ef
P2860
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.